Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool May 28, 2008 Brian Lawler	King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another.
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool August 14, 2009 Brian Orelli	The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet.
The Motley Fool November 10, 2005 W.D. Crotty	Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool June 11, 2008 Brian Lawler	Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals?
The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
The Motley Fool February 27, 2004 Zeke Ashton	King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back.
The Motley Fool March 1, 2007 Brian Lawler	King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter.
The Motley Fool April 1, 2008 Brian Lawler	A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool June 24, 2011 Brian Orelli	Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why?
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool June 20, 2011 Brian Orelli	Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool April 26, 2011 Brian Orelli	We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool November 2, 2007 Brian Lawler	A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note.
The Motley Fool September 18, 2007 Brian Lawler	Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
Pharmaceutical Executive June 1, 2006 Sara Calabro	King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool August 29, 2011 Brian Orelli	A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
The Motley Fool September 8, 2006 Brian Lawler	Ligand's Drug Sale For the pharmaceutical's marketed drugs, everything must go. Investors, take note.
The Motley Fool January 6, 2012 David Williamson	Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares.
The Motley Fool December 13, 2007 Brian Lawler	Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down.
The Motley Fool September 4, 2007 Rich Duprey	Pain in Mylan's Future Competition for painkiller patch may prove to be a major pain for the generics maker Mylan. The stock has dropped precipitously from its highs, and while it's recovered some, its immediate outlook is cloudy.
The Motley Fool June 27, 2011 Brian Orelli	Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections.
The Motley Fool May 2, 2007 Brian Lawler	Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool November 13, 2006 Brian Lawler	King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.
The Motley Fool October 29, 2004 Bill Mann	King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
The Motley Fool December 9, 2008 Brian Orelli	Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings.
The Motley Fool May 31, 2011 Brian Orelli	Pay Attention, Biotech Investors Competitors and partners can't be ignored.
The Motley Fool June 23, 2008 Brian Lawler	Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
Pharmaceutical Executive December 1, 2013	FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.
The Motley Fool July 1, 2008 Brian Orelli	As the FDA Generics Office Turns The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool March 23, 2007 Brian Lawler	Ligand's Big Payout Ligand decides to return some cash to shareholders.